[Featured Stock] T&R Biofab Selected for Cover Paper in International Journal for EpibioTech Hair Loss Treatment↑

T&R Biofab is showing strong performance. This is interpreted as being influenced by the news that the hair loss treatment developed jointly with Epibiotech, with which they signed a Memorandum of Understanding (MOU), was selected as the cover paper of an international academic journal.

As of 9:11 AM on the 11th, T&R Biofab is trading at 12,700 KRW, up 10.24% compared to the previous day.

According to industry sources the day before, Epibiotech, a specialized research and development company for hair loss treatments, had its research paper on the allogeneic dermal papilla cell hair loss treatment EPI-008 selected as the cover paper for the July issue of the prestigious international dermatology journal 'Experimental Dermatology.'

Epibiotech is developing dermal papilla cells as an allogeneic cell therapy. They confirmed that when lab-scale produced dermal papilla cells were administered to pig skin, both the number and thickness of hair follicles significantly increased. This first hair growth experiment using pigs attracted academic attention and was selected as the cover paper for the July issue.

Meanwhile, according to the Financial Supervisory Service's electronic disclosure, T&R Biofab signed an MOU with Epibiotech in 2021 for the joint development of stem cell treatments targeting hair loss diseases using induced pluripotent stem cells.